MedTrace Logo

Neostigmine and Glycopyrrolate by Iontophoresis

NCT06351995 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2024-04-08

No results posted yet for this study

Summary

To determine a lower effective dose of neostigmine to induce bowel evacuation by transcutaneous administration by iontophoresis.

Conditions

  • Spinal Cord Injuries
  • Constipation
  • Fecal Incontinence
  • Neurogenic Bowel

Interventions

DRUG

Combination of Neostigmine and Glycopyrrolate

Intravenous or transdermal

DEVICE

I-Box by Dynatronics

Electric field conducting drugs through the skin without compromising its integrity

Sponsors & Collaborators

  • James J. Peters Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Christopher P Cardozo, MD · James J. Peters Veterans Affairs Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-06
Primary Completion
2022-10-25
Completion
2025-01-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06351995 on ClinicalTrials.gov